ArticleBiosensors & bioelectronics2021
Fluorescence polarization system for rapid COVID-19 diagnosis.
Article in Biosensors & bioelectronics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 3 syntheses or guidelines pooled it, 64 citations in OpenAlex.
- Evaluation of CRISPR-Based Assays for Rapid Detection of SARS-CoV-2: A Systematic Review and Meta-Analysis.Yonsei medical journal · 2022Pooled it
- Accuracy of clustered regularly interspaced short palindromic repeats (CRISPR) to diagnose COVID-19, a meta-analysis.Microbial pathogenesis · 2022Pooled it
- Diagnostic efficiency of RPA/RAA integrated CRISPR-Cas technique for COVID-19: A systematic review and meta-analysis.PloS one · 2022Pooled it
- Disease Biomarker Detection Using Fluorescence Polarization Assays: Principles and Clinical Applications.Diagnostics (Basel, Switzerland) · 2026Review
- News Fluorescence-Based Polarization Immunoassays as a Frontline Test for the Rapid Detection of Acute and Late Phase Lyme-Borreliosis Disease.Molecules (Basel, Switzerland) · 2026Article
- Porous GNPs assisted LAMP-CRISPR/Cas12a amperometric biosensor as a potential point of care testing system for SARS-CoV-2.Mikrochimica acta · 2025Article
- Recent Advances in Clustered Regularly Interspaced Short Palindromic Repeats/CRISPR-Associated Proteins System-Based Biosensors.Biosensors · 2025Review
- Fluorescence Polarization Assay for Infection Diagnostics: A Review.Molecules (Basel, Switzerland) · 2024Review
- Empowering the on-site detection of nucleic acids by integrating CRISPR and digital signal processing.Nature communications · 2024Article
- Evolution and Impact of Nucleic Acid Amplification Test (NAAT) for Diagnosis of Coronavirus Disease.Analytical chemistry · 2024Review
- Recent Advances in Field-Effect Transistor-Based Biosensors for Label-Free Detection of SARS-CoV-2.Small science · 2024Article
- DNA Probes for Cas12a-Based Assay with Fluorescence Anisotropy Enhanced Due to Anchors and Salts.Biosensors · 2023Article
- Recent progress on rapid diagnosis of COVID-19 by point-of-care testing platforms.Chinese chemical letters = Zhongguo hua xue kuai bao · 2023Review
- CRISPR-Enhanced Hydrogel Microparticles for Multiplexed Detection of Nucleic Acids.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Article
- Review
- In Silico Evaluation of CRISPR-Based Assays for Effective Detection of SARS-CoV-2.Pathogens (Basel, Switzerland) · 2022Review
- Nanomaterials Used in Fluorescence Polarization Based Biosensors.International journal of molecular sciences · 2022Review
- CRISPR-Cas systems for diagnosing infectious diseases.Methods (San Diego, Calif.) · 2022Review
- Diagnostics of COVID-19 Based on CRISPR-Cas Coupled to Isothermal Amplification: A Comparative Analysis and Update.Diagnostics (Basel, Switzerland) · 2022Review
- A one-pot CRISPR/Cas13a-based contamination-free biosensor for low-cost and rapid nucleic acid diagnostics.Biosensors & bioelectronics · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 2 countries.
Funding
Abstract
Prompt diagnosis, patient isolation, and contact tracing are key measures to contain the coronavirus disease 2019 (COVID-19). Molecular tests are the current gold standard for COVID-19 detection, but are carried out at central laboratories, delaying treatment and control decisions. Here we describe a portable assay system for rapid, onsite COVID-19 diagnosis. Termed CODA (CRISPR Optical Detection of Anisotropy), the method combined isothermal nucleic acid amplification, activation of CRISPR/Cas12a, and signal generation in a single assay, eliminating extra manual steps. Importantly, signal detection was based on the ratiometric measurement of fluorescent anisotropy, which allowed CODA to achieve a high signal-to-noise ratio. For point-of-care operation, we built a compact, standalone CODA device integrating optoelectronics, an embedded heater, and a microcontroller for data processing. The developed system completed SARS-CoV-2 RNA detection within 20 min of sample loading; the limit of detection reached 3 copy/μL. When applied to clinical samples (10 confirmed COVID-19 patients; 10 controls), the rapid CODA test accurately classified COVID-19 status, in concordance with gold-standard clinical diagnostics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.